GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
Executive Summary
GlaxoSmithKline is discussing with FDA whether Paxil data indicating an increased risk of "emotional lability" in pediatric patients on paroxetine should be communicated to physicians